Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $8,215,315.38 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 89,433 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $91.86, for a total transaction of $8,215,315.38. Following the sale, the chief executive officer directly owned 869,881 shares in the company, valued at approximately $79,907,268.66. The trade was a 9.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Down 8.1%

KNSA stock opened at $88.34 on Friday. Kiniksa Pharmaceuticals International, plc has a 52 week low of $37.02 and a 52 week high of $98.48. The company has a fifty day simple moving average of $80.18 and a two-hundred day simple moving average of $61.10. The firm has a market capitalization of $6.89 billion, a P/E ratio of 67.95 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. As a group, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Curry Webb Wealth Management LLC bought a new position in Kiniksa Pharmaceuticals International during the third quarter valued at $29,000. Allworth Financial LP raised its stake in shares of Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. Nykredit A S bought a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth about $34,000. Jacobi Capital Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth about $48,000. Finally, KBC Group NV bought a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth about $34,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of analyst reports. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. Canaccord Genuity Group boosted their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. The Goldman Sachs Group upped their price objective on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Finally, Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.57.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.